Kornimate/medical-research-clean huggingface dataset:
effect of health belief model education on water intake in the elderly (hbm-water study)

Conditions: Dehydration; Water Consumption in Elderly

Summary: the purpose of this study is to evaluate the effectiveness of a health belief model (hbm)-based education program to increase daily water consumption among elderly individuals aged 65 and above. participants will be divided into two groups; one group will receive hbm-based education, and the other group will not receive any education. the effects of the education program on daily water consumption and dehydration symptoms will be assessed.

the study has a randomized controlled design and will last 1 month. the study group will be given a health belief model (hbm)-based training program for 1 month, and the same training will be given again after 2 weeks to reinforce the training, while the control group will not receive any training. participants; daily water consumption will be collected and dehydration symptoms will be evaluated at baseline and at the end of 1 month, and differences between groups will be analyzed.

Eligibility criteria:
inclusion criteria: aged 65 years and older. consuming less than 1000 ml of water daily. exclusion criteria: scoring below 17 on the mini-mental state examination. being bedridden. having a medical condition that requires fluid restriction. taking diuretic medications. withdrawal criteria: elderly participants who wish to withdraw from the study at any stage of the research process. participants who meet the exclusion criteria during the study period.

Keywords: health belief model elderly hydration education program
executive functions and preterm children in 3 to 4 year old

Conditions: Preterm Infant

Summary: preterm children have a high risk for neurodevelopmental impairments. the impact on motor functions and neurosensory functions is demonstrated but the incidenceof executive functions is not described for preterm infants.

it is an epidemiologic, observational, prospective study. all patients, included in the lift cohort, in 3 to 4 year old during the period study, are contacted by mail. patientswith congenital anomalies or genetic syndromes are excluded. children with parents who do not speak french are excluded. antenatal and postnatal criteria known to be associated with disorders of executive functions are collected as, gestational age, sex, multiple pregnancy, intrauterine growth retardation, antenatal or postnatal steroid use, breastfeeding, cerebral injuries and socio-economic status. after a couple of weeks, parents are contacted by a study manager, by phone call, to collect parental consent and answer parental questions. after consent collect, brief questionnaires are sending. if they wish, parents could give the brief teacher questionnaire to the mean teacher. teachers send by themselves their response. an informatic version is available with a personal link given especially by mail for each child. all data are anonymous. brief questionnaire is composed of 63 items, exploring 2 main domains: behavior and metacognition. twenty minutes are necessary to complete questionnaire. in case of no questionnaire return after one month, parents are contacted by phone. the investigators hypothesize a lost to follow-up at 0.25 and no response at 0.35. the response expected is 300 questionnaires.

Eligibility criteria:
inclusion criteria: * patient in 3 to 4 year old, included in lift cohort exclusion criteria: * congenital abnormalities including nervous system malformations; genetic diseases; incomplete understanding of written and oral french by parents
effects of global hip versus isolated abductors strengthening exercises in patients withsecondary piriformis syndrome

Conditions: Piriformis Syndrome

Summary: the study will be a randomized controlled trial. twenty-four subjects will be assigned randomly by using the lottery method into two groups. group a will be given a hot pack in addition to the global hip muscles strengthening exercise while group b is the control group which will receive a hot pack in addition to hip abductor strengthening. the time duration will be 6 weeks. pain intensity will be assessed by nprs.3 sessions per week will be given for 6 weeks. outcome measures will be taken at baseline, in 3rd week, and at the end of the 6th week.

secondary piriformis syndrome is a common condition of extra-spinal sciatica which is related to or around the piriformis muscle and irritates the sciatic nerve. most cases reported are of secondary piriformis syndrome. secondary piriformis syndrome is caused due to soft tissue inflammation, and muscular spasms, which result in nerve compression. inflammation occurs due to trauma on the buttock and piriformis muscle contractures. strengthening exercise program is another physical technique that has been supported by research in numerous areas, which has effects on the reduction of pain, range of motion, and lower extremity function. this study will aim to compare the effects of global hip muscles and isolated hip abductors muscle strengthening exercise programs on pain, range of motion, and lower extremity function in patients with secondary piriformis syndrome. the study will be a randomized controlled trial. twenty-four subjects will be assigned randomly by using the lottery method into two groups. group a will be given a hot pack in addition to the global hip muscles strengthening exercise while group b is the control group which will receive a hot pack in addition to hip abductor strengthening. the time duration will be 6 weeks. pain intensity will be assessed by nprs.3 sessions per week will be given for 6 weeks. outcome measures will be taken at baseline, in 3rd week, and at the end of the 6th week. the collected data will be analyzed in the statistical package for the social sciences (spss) 25.parametric/non-parametric tests will be applied after testing the normality of the data.

Eligibility criteria:
inclusion criteria: * both genders * age: 20-50 years * batty test to diagnose secondary piriformis syndrome exclusion criteria: * diagnosed congenital spinal defects * diagnosed hip arthritis * pregnancy * diagnosed disc facet pathology * history of spinal trauma * musculoskeletal abnormality in the lumbar spine * diagnosed rheumatologic disorders * any diagnosed bony or soft tissue systemic disease
comparative pharmacokinetic study between two extended-release cilostazol formulations in korea

Conditions: Peripheral Artery Disease

Summary: this is a randomized, open-label, multiple-dose, two-sequence, two-period crossover study to to compare the safety/tolerability and pharmacokinetics between pletaal sr cap. and cilostan cr tab. in healthy volunteers

eligibility for participation of this study will be determined from demographic information, medical history, physical examination, electrocardiogram (ecg) and clinical laboratory tests within 4 weeks before study drug administration. subjects suitable for this study will be admitted to the clinical trial center of cha bundang medical center on the day before dosing (day -1). from day 1 to 5, subjects will be dosed study drug (pletaal sr cap. 200 mg once a day or cilostan cr tab. 200mg once a day). pharmacokinetic samplings will be done upto 24 hours after 1st study drug dosing and upto 72 hours after 5th study drug dosing. after 9 days of washout period (day 15), subjects will be dosed study drug and pharmacokinetic samplings will be done by crossover manner.

Eligibility criteria:
inclusion criteria: * healthy male subjects aged 20 - 45 years * bmi (body mass index) between 18.0 and 27.0 * agreement with written informed consent exclusion criteria: * clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal disease or mental disorder (past history or present) * inadequate result of laboratory test (especially, alt/ast/r-gtp/alp/ldh/total bilirubin \> 1.5 x unl) * positive reaction in the hbs ag, anti-hcv ab, anti-hiv ab * taking otc (over the counter) medicine including oriental medicine within 7 days * clinically significant allergic disease * subject with known for hypersensitivity reaction to cilostazol * previous whole blood donation within 60 days or component blood donation within 30 days * previous participation of other trial within 90 days * continued taking caffeine (caffeine \> 5 cup/day), drinking (alcohol \> 30 g/day) and severe heavy smoker (cigarette \> 1/2 pack per day)
retrospective chart review study of pediatric patients treated with korlym for cushing syndrome

Conditions: Hypercortisolism; Cushing Syndrome

Summary: this retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with korlym for cushing's syndrome.

this retrospective chart review study seeks to collect data from pediatric patients treated with korlym (mifepristone) to help provide clinicians with some insight on the potential role of mifepristone in the treatment of pediatric patients with cushing syndrome. only sites that have been identified to have patients appropriate for this protocol will be invited to participate and contribute data on their patients data to be collected from a retrospective chart review will include: * patient demographics * medical history * pre and post treatment clinical assessments and laboratory results * radiologic findings (if available) * adverse events data will be collected for all follow-up visits, up until the most recent encounter prior to irb approval.

Eligibility criteria:
inclusion criteria: * pediatrics (age≤21 years) at time korlym initiation * considered to have a diagnosis of endogenous cushing's syndrome by the healthcare provider * received at least one dose of korlym * availability of pre-treatment (baseline) and follow-up data exclusion criteria: * none

Keywords: cushing syndrome, hypercortisolism
telemonitoring for the recuperation of patients with cpap

Conditions: Apnea, Obstructive

Summary: this study is aimed at patients who do not achieve a minimum (≥4 hours/night) or optimal (≥5,5 hours/night) use of continuous positive airway pressure (cpap) treatment and it is proposed to improve their adherence making a 4-weeks intervention using telemedicine tools: cpap remote monitoring, a mobile application (app) and a voicemail. the concept of this work is to "recover" patients to minimum or optimal cpap use.

given the prevalence of obstructive sleep apnea (osa), the symptoms it produces, which is a risk factor for various entities and that, in addition, its treatment clearly improves others; its control must be optimized in an effective and cost-effective manner. the use of information and communication technologies (ict) in this context can be very beneficial. the design of the study is prospective, randomized, controlled, open and parallel. a ict-based out of hospital management of osa is implemented to be compared with the classical in-hospital management. the main objectives were to evaluate the effectiveness of of two osa management programs: the in-hospital classic management versus a telemedicine program based on the use of icts in the recovery of patients with osa who who do not meet the minimum treatment (4 hours) or in those who do not comply with the optimal use (5.5 hours). this is a 4-weeks management randomized, with parallel groups study. participants will be patients from the sleep unit of hospital clinic barcelona with osa diagnosis and cpap treatment indication, who after a follow-up between 3-months and up to 5 years have a cpap compliance below 5,5 hours/night. two management programs will be compared: * in-hospital classic management: patients are followed regularly in the hospital with a face-to-face visit by the sleep unit nurse. * telemedicine management: telemedicine support with mobile app, voicemail and cpap remote monitoring.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, * cpap treatment initiated ≥1 month and \<12 months * cpap compliance below 5.5 hours per night, * regular use of smartphone and mobile apps. exclusion criteria: * clinical suspicion or other confirmed sleep pathology, * severe nasal obstruction that prevents the use of cpap, * physical-psychological inability to follow questionnaires and the program, * patients undergoing uvulopalatopharyngoplasty, * cheyne-stokes syndrome, * pregnancy, * rejection in the initial test with cpap during the training and education session and * failure to obtain informed consent.
strength training on pancreatic cancer

Conditions: Pancreatic Neoplasms; Cachexia; Myopathy

Summary: the purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive hearing loss in both ears due to autoimmune inner ear disease (aied).

sudden out-of-hospital cardiac arrest (ooh-ca) remains a significant cause of death, in spite of recent declines in overall mortality from cardiovascular disease. existing methods of emergency resuscitation are inadequate due to time delays inherent in the transport of a trained responder with defibrillation capabilities to the side of the ooh-ca victim. existing emergency medical services (ems) systems typically combine paramedic emergency medical technician (emt) services with some level of community involvement, such as bystander cardiopulmonary resuscitation (cpr) training. some communities include automated external defibrillators (aeds) at isolated sites or in mobile police or fire vehicles. a comprehensive, integrated community approach to treatment with aeds would have community units served by these volunteer non-medical responders who can quickly identify and treat a patient with ooh-ca. such an approach is termed public access defibrillation (pad).

Eligibility criteria:
inclusion criteria: * patients with pancreatic carcinomas after surgery (resection or exploration) * given consent exclusion criteria: * acute infection * pain * no mobility or ability for walking or standing * severe neurological disorders (apoplex, morbus parkinson, paresis of the lower extremeties) * severe cardiac or cardiovascular diseases (z.b. heart insufficiency nyha iii, myocardial infarction \<3 months) * rhytmical disorders, that contraindicate ergospirometric examinations * cardiac therapy with digitalis pharmacy * unclear syncopes * severe pulmonal insufficiency * renal insufficiency (gfr \ 3 mg/dl) * synchronous participation in an other clinical trial
evaluation of different anchorage-supported appliances and expansion procedures for face mask treatment

Conditions: Malocclusion, Angle Class III

Summary: the purpose of this study is to assess and compare the effect of two appliances (hybrid-hyrax expander/ bonded rapid maxillary expander (rme)) supported by different anchorage units and two different expansion procedures (routine rapid maxillary expansion protocol (routine)/ alternative rapid expansion and constriction protocol (alt-ramec)) on maxillary protraction during face mask (fm) treatment.

face mask therapy is an effective method in the treatment of class iii malocclusions due to maxillary insufficiency. in face mask treatment, various intraoral devices are used to transmit protraction forces to the maxilla. according to the anchorage unit, these appliances are divided into tooth-supported and bone-supported. the traditional bonded rapid maxillary expander (rme) is a tooth-supported appliance that allows expansion and is generally used with face masks. however, it causes many side effects due to the transmission of protraction forces through the teeth. hybrid appliances supported by skeletal and dental anchorage may be preferred over bonded rme in the maxilla for face mask treatment based on their lower dental side effects and high skeletal contribution. before transferring the protraction forces to the maxilla using a face mask, expansion is first performed with intraoral devices according to the patient's needs. for this purpose, two different expansion procedures are currently used: routine rapid maxillary expansion (routine) and alternative rapid maxillary expansion and contraction (alt-ramec). in the routine rapid maxillary expansion procedure, the expander screw is turned twice a day until the expansion phase is complete. unlike the routine procedure, in the alt-ramec procedure, each week of expansion is followed by a week of contraction. the duration of the expansion-contraction process varies between 7-9 weeks, depending on the patient's need for expansion. these opening and closing phases are increased maxillary protraction by loosening the intermaxillary sutures. the main purpose of this study is to compare the effects of different combinations of appliances and procedures on maxillary protraction during face mask treatment and determine the most powerful method. sixty patients who were planned to apply face mask treatment were included in the study and divided into four groups (n=15) (group 1: hybrid-hyrax expander and alt-ramec procedure, group 2: bonded rme and alt-ramec procedure, group 3: hybrid hyrax expander and routine protocol, group 4: bonded rme and routine protocol). to investigate skeletal changes, lateral cephalometric films were taken before (t0) and after (t1) treatment. dolphin imaging software and autocad 2023 software were used for cephalometric measurements.

Eligibility criteria:
inclusion criteria: * skeletal class iii * prepubertal growth stage * reverse overjet exclusion criteria: * previous orthodontic treatment history * patients with craniofacial abnormalities and syndromes. * systemic diseases

Keywords: facemask treatment
a multiple-dose study to evaluate mk-1075 in hepatitis c virus (hcv) infected participants (mk-1075-004)

Conditions: Hepatitis C Virus Infection

Summary: this study will evaluate safety, pharmacokinetics (pk), and the ability of mk-1075 to suppress viral load (vl) in hcv-infected participants during 7 days of once daily dose administration. the primary hypothesis is at a once-daily dose that is sufficiently safe and well tolerated in hcv-infected participants, the mean maximum hcv rna (log10 iu/ml) reduction is at least 3 log10 iu/ml as compared to baseline following multiple dose oral administration of mk-1075 in hcv genotype 1 (gt1) and genotype 3 (gt3) infected participants.


Eligibility criteria:
inclusion criteria: * female of non-childbearing potential * have a body mass index (bmi) \>=18 to =\< 37 kg/m\^2 * excepting hcv infection, be in good health * have a clinical diagnosis of chronic hcv infection, exclusively gt1 or exclusively gt3 * agree to follow smoking restrictions exclusion criteria: * has a history of clinically significant, not stably controlled endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases. * have been treated with amiodarone within the prior year, or is currently on beta-blockers or verapamil * has a history of cancer (malignancy) * has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food * is positive for hepatitis b surface antigen or human immunodeficiency virus (hiv) * has had major surgery, donated or lost approximately 500 ml blood within 4 weeks prior to screening visit * has participated in another drug trial within 4 weeks prior to screening visit * is taking a non-permitted medication to treat a co-morbid condition * consumes greater than 2 glasses of alcoholic beverages * is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 12 months * has evidence or history of chronic hepatitis not caused by hcv, including but not limited to non-hcv viral hepatitis, non-alcoholic steatohepatitis (nash), drug-induced hepatitis, or autoimmune hepatitis * has been treated with other hcv inhibitors, such as sofosbuvir or vx-135 * has evidence of advanced or decompensated liver disease, bridging fibrosis or higher grade fibrosis from a prior liver biopsy
ureteric stenting versus non-stenting following uncomplicated ureteroscopic lithotripsy

Conditions: Ureter Stone

Summary: this study aims to compare three groups of patients who underwent uncomplicated ureteroscopic lithotripsy (ursl) to evaluate whether stents could be eliminated after the procedure


Eligibility criteria:
inclusion criteria: * age 18 years or older * unilateral ureteric stones managed by ureteroscopy exclusion criteria: * stone size \< 2 cm * bilateral ureteral stones * incomplete stone removal due to impacted stones * failed ureteroscopic access to the stone * stone migration to the kidney * pregnancy * active urinary tract infection * solitary kidney * ureteral stent placed preoperatively * severe mucosal injury or perforation * suspected additional ureteral pathology such as ureteral stricture * urothelial carcinoma or polyp.
correlation between h.pylori colonization and gastritis

Conditions: Gastritis H Pylori

Summary: to study the prevelance rate of h.pylori colonization in patients with gastritis. to correlate the h.pylori colonization with endoscopic finding. to correlate both h.pylori colonization and endoscopic finding with clinical manifestation.

helicobacter pylori is a gram negative microaerophilic spiral bacterium that is usually found in the stomach and thereby cause infection , which is associated with varying degrees of damage of superficial and glandular epithelium. chronic gastritis is a histological entity that is defined by an inflammatory infiltrate of lymphoblasma cells, cocsometimes polynuclear neutrophils and by progressive glandular atrophy of the gastric mucosa,and probably the main cause of chronic inflammation in the gastric mucosa which is usually caused by h.pylori infection. in addition to chronic gastritis almost all benign gastroduodenal diseases including peptic ulcer , mucosa associated lymphoid tissue lymphoma and malignant gastroduodenal adenocarcinoma occurs due to previous h.pylori infection that is usually started with gastric precancerous lesion, gastric atrophy , gastric intestinal metaplasia , dysplasia and then turned to gastric carcinoma. so the evaluation of h.pylori infection status yo non-infection, past infection, current infection by endoscopy has therefore become increasingly important. the sydney grading system is one of the most important recognised tools yo charactize histological lesions of chronic gastritis. the system categorise gastritis according to intensity of mononuclear inflammatory cellular infiltrate , polymorph activity , atrophy , intestinal metaplasia and h.pylori density into mild , moderate and severe categories, but up till now there is non-standard histology reporting formats are still widely used for gastritis and even specialists are often frustrated by the histological definition that make it difficult to identify candidates for clinico-endoscopic surveillance. therefore the eradication of this bacterium aimed to interrupt the carcinogenesis process and prevent recurrence of gastritis and peptic ulcer disease. however despite of the significant researches conducted on h.pylori colonization in gastric mucosa and its association with endoscopic finding and severity of clinical manifestations, and its impact on the egyptian population is still a topic of debate. currently, there is no study has definitively determined this relationship in the egyptian population despite the high prevalence rate of h.pylori infection

Eligibility criteria:
inclusion criteria: - all patients with gastritis above 18 years old with chronic h.pylori infection documented by histological examination included in the study. exclusion criteria: all patients mentioned above who have previous gastrointestinal surgery and patients below 18y .